Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN008 with re-irradiation in recurrent glioblastoma
CTR20182067Phase 2Terminated
- Sponsor
- CANbridge Pharmaceuticals Inc.
- Start
- Nov 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of asunercept in glioblastoma (GBM), sponsored by CANbridge Pharmaceuticals Inc.. Started Nov 2018; status: terminated.
02
Drugs
asunercept
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20182067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182067.